Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01808534 · OUTCOME

Progression Free Survival (PFS)

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors · Source last updated 2015-07-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
90% Confidence Interval
Time frame
Up to 2 years

What was measured

Summarized by Kaplan-Meier methods including 90% confidence intervals for the median using method of Brookmeyer and Crowley. Time until progression, death or last evaluation will be calculated. If a patient did not progress or die, they will be censored at their last evaluation in the analysis.

Analysis population: All patients who enrolled and received treatment.

Groups in this outcome

Treatment (Palifosfamide)

Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Palifosfamide)5

Reported measurements

Source class 1
Values in months · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Palifosfamide)0.69Not reported0.076.18Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.07
        upper Limit
        6.18
        value
        0.69
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    units
    Participants
description
Summarized by Kaplan-Meier methods including 90% confidence intervals for the median using method of Brookmeyer and Crowley. Time until progression, death or last evaluation will be calculated. If a patient did not progress or die, they will be censored at their last evaluation in the analysis.
dispersion Type
90% Confidence Interval
groups
  1. description
    Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Palifosfamide)
param Type
MEDIAN
population Description
All patients who enrolled and received treatment.
reporting Status
POSTED
time Frame
Up to 2 years
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice